These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The role of standard-dose cytarabine in children with acute promyelocytic leukemia: a single-center experience.
    Author: Zhang L, Zhu X, Chen X, Chen Y, Zou Y.
    Journal: J Pediatr Hematol Oncol; 2011 Mar; 33(2):e46-50. PubMed ID: 21127433.
    Abstract:
    BACKGROUND: There are very limited data reported about the role of cytarabine (Ara-C) in childhood acute promyelocytic leukemia (APL). We review the clinical course and treatment outcome of APL and explore the role of standard-dose Ara-C for children. PROCEDURE: Between January 1999 and December 2008, 36 children (<14 y) with newly diagnosed APL were included. RESULTS: The overall complete remission rate was 97.2% (35/36). Two patients were lost to follow-up after induction. Two groups of patients were identified according to different consolidation chemotherapy regimens. Seventeen patients were given polychemotherapy in combination with standard-dose Ara-C (group I), 16 patients were given daunorubicin alone (group II). Although the 5-year estimate of disease-free survival between groups I and II had no statistically significant difference (P = 0.614), there was a 12% higher disease-free survival rate for group I. CONCLUSION: Standard-dose Ara-C might play some role in the consolidation treatment of children suffering from APL.
    [Abstract] [Full Text] [Related] [New Search]